Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

ADMA BIOLOGICS, INC.

CIK 1368514 ADMA·Biological Products · All EDGAR filings ↗

Progression

  1. SEC comment letter CORRESP
  2. Accounting standard newly cited 10-Q +70d
Refine
Form
An amendment is grouped with the report it amends; every 12b-25 notice is one group

Accounting standard newly cited Filing comparison

ADMA BIOLOGICS, INC. cited accounting standard ASU 2016-02 for the first time in this filing series

The filing states this standard was adopted in 2019, so this is the first time it has been cited in this series rather than a change of policy in the current period.

Upon adoption of ASU 2016-02, Leases (Topic 842) effective January 1, 2019, the Company elected the package of practical expedients, which permits the Company to not reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs.
Evidence
Adopted
2016-02
Adoption year stated
2019
Caveat
The filing states this standard was adopted in 2019, so this is the first time it has been cited in this series rather than a change of policy in the current period.
Contexts
Upon adoption of ASU 2016-02, Leases (Topic 842) effective January 1, 2019, the Company elected the package of practical expedients, which permits the Company to not reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs.
New standards
2016-02, 2025-11
Prior filed
2025-11-05
Prior form
10-Q
Restates existing policy
Yes
Source
accounting standards update (ASU) reference comparison
Why
An accounting standard (ASU) appears in this filing that did not appear in the previous comparable one, in a sentence describing it as adopted. That is a change in what the company discloses, which is not always a change of policy in the current period: the filing may state an adoption date years earlier.

Source filing ↗ Prior filing ↗

SEC comment letter Filing comparison

ADMA BIOLOGICS, INC. responded to SEC staff comments on MD&A

Letter dated 2025-07-23; published on EDGAR 2026-02-25 — the SEC releases comment letters only after the review closes.

We note your analysis of revenues for the periods presented on pages 73 and 75, including the 65% increase in revenue in 2024 and improved operating results which contributed to net income on a GAAP basis for the first time, and your expectation of increased physician, payer and patient acceptance and utilization of ASCENIV, as well as sales increases for some of your other IG products. Please address the following…
Evidence
Direction
company to staff
Letter dated
2025-07-23
Published on edgar
2026-02-25
Reviewing
ADMA Biologics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 18, 2025 File No. 001-36728 Dear Ms. Do and Mr. Vaughn: On behalf of ADMA
Source
Company response to SEC staff (CORRESP)
Topics
MD&A, Segment reporting, Inventory, Income taxes
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.

Source filing ↗

SEC comment letter Filing comparison

ADMA BIOLOGICS, INC. responded to SEC staff comments on MD&A

Letter dated 2025-08-13; published on EDGAR 2026-02-25 — the SEC releases comment letters only after the review closes.

Evidence
Direction
company to staff
Letter dated
2025-08-13
Published on edgar
2026-02-25
Reviewing
ADMA Biologics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 18, 2025 File No. 001-36728 Dear Ms. Do and Mr. Vaughn: On behalf of ADMA
Source
Company response to SEC staff (CORRESP)
Topics
MD&A, Segment reporting
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.

Source filing ↗

SEC comment letter Filing comparison

ADMA BIOLOGICS, INC. responded to SEC staff comments on MD&A

Letter dated 2025-09-26; published on EDGAR 2026-02-25 — the SEC releases comment letters only after the review closes.

Please revise your future filings accordingly. Response: The Company respectfully acknowledges the Staff’s comment and will revise future filings accordingly. Commencing with the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2025, and continuing in Quarterly Reports on Form 10-Q beginning thereafter, the Company will expand its discussion of revenue performance by respective Immune…
Evidence
Direction
company to staff
Letter dated
2025-09-26
Published on edgar
2026-02-25
Reviewing
ADMA Biologics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 18, 2025 File No. 001-36728 Dear Ms. Do and Mr. Vaughn: On behalf of ADMA
Source
Company response to SEC staff (CORRESP)
Topics
MD&A
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.

Source filing ↗

SEC comment letter Filing comparison

SEC staff questioned ADMA BIOLOGICS, INC.'s accounting for MD&A

Letter dated 2025-07-16; published on EDGAR 2026-02-25 — the SEC releases comment letters only after the review closes.

We note your analysis of revenues for the periods presented on pages 73 and 75, including the 65% increase in revenue in 2024 and improved operating results which contributed to net income on a GAAP basis for the first time, and your expectation of increased physician, payer and patient acceptance and utilization of ASCENIV, as well as sales increases for some of your other IG products. Please address the following…
Evidence
Direction
staff to company
Letter dated
2025-07-16
Published on edgar
2026-02-25
Reviewing
ADMA Biologics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 18, 2025 File No. 001-36728 Dear Brad Tade: We have limited our review of
Source
SEC staff comment letter (UPLOAD)
Topics
MD&A, Segment reporting, Inventory, Income taxes
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.

Source filing ↗

SEC comment letter Filing comparison

SEC staff questioned ADMA BIOLOGICS, INC.'s accounting for MD&A

Letter dated 2025-07-30; published on EDGAR 2026-02-25 — the SEC releases comment letters only after the review closes.

Evidence
Direction
staff to company
Letter dated
2025-07-30
Published on edgar
2026-02-25
Reviewing
ADMA Biologics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 18, 2025 File No. 001-36728 Dear Brad Tade: We have reviewed your July 23
Source
SEC staff comment letter (UPLOAD)
Topics
MD&A, Segment reporting
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.

Source filing ↗

SEC comment letter Filing comparison

SEC staff questioned ADMA BIOLOGICS, INC.'s accounting for MD&A

Letter dated 2025-09-16; published on EDGAR 2026-02-25 — the SEC releases comment letters only after the review closes.

Evidence
Direction
staff to company
Letter dated
2025-09-16
Published on edgar
2026-02-25
Reviewing
ADMA Biologics, Inc. Form 10-K for the fiscal year ended December 31, 2024 Filed March 18, 2025 File No. 001-36728 Dear Brad Tade: We have reviewed your August
Source
SEC staff comment letter (UPLOAD)
Topics
MD&A
Why
SEC staff reviewed the company's periodic report and raised written comments on its accounting, or the company replied to them. Letters are published on EDGAR only after the review closes.

Source filing ↗